Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Blau Farmaceutica does not have enough data to calculate 10-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Blau Farmaceutica 10-Year RORE % Related Terms
Blau Farmaceutica 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: 10-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 10-year before.
Blau Farmaceutica (BSP:BLAU3) has a 10-Year RORE % of 0.00 as of Jun. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Blau Farmaceutica and its competitors. According to the industry distribution chart, Blau Farmaceutica ranks #999999 out of 671 companies in the Drug Manufacturers industry.
Is Blau Farmaceutica's 10-Year RORE % too high?
Blau Farmaceutica's current 10-Year RORE % is 0.00. Based on the distribution chart, Blau Farmaceutica ranks #999999 out of 671 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Blau Farmaceutica has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's 10-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #999999 out of 671 companies for 10-Year RORE %. This places Blau Farmaceutica in the lower half of its industry. The industry median 10-Year RORE % is 5.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 5.96, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 5.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$10.67, compared to a current price of R$8.99 — trading 15.7% below its estimated fair value. The current 10-Year RORE % is 0.00. Blau Farmaceutica's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current 10-Year RORE % is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.99 is trading 15.7% below its estimated GF Value™ of R$10.67.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
10-Year RORE %: 0.00
GF Value™: R$10.67 vs. price of R$8.99 (15.7% below fair value)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
84GF Score
Get the complete analysis for BSP:BLAU3
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
